346 related articles for article (PubMed ID: 19208845)
21. Faster replication and higher expression levels of viral glycoproteins give the vesicular stomatitis virus/measles virus hybrid VSV-FH a growth advantage over measles virus.
Ayala-Breton C; Russell LO; Russell SJ; Peng KW
J Virol; 2014 Aug; 88(15):8332-9. PubMed ID: 24829351
[TBL] [Abstract][Full Text] [Related]
22. Antibody Screening System Using a Herpes Simplex Virus (HSV)-Based Probe To Identify a Novel Target for Receptor-Retargeted Oncolytic HSVs.
Ikeda H; Uchida H; Okubo Y; Shibata T; Sasaki Y; Suzuki T; Hamada-Uematsu M; Hamasaki R; Okuda K; Yamaguchi M; Kojima M; Tanaka M; Hamada H; Tahara H
J Virol; 2021 Apr; 95(9):. PubMed ID: 33627393
[TBL] [Abstract][Full Text] [Related]
23. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter.
Hasegawa K; Pham L; O'Connor MK; Federspiel MJ; Russell SJ; Peng KW
Clin Cancer Res; 2006 Mar; 12(6):1868-75. PubMed ID: 16551872
[TBL] [Abstract][Full Text] [Related]
24. Chemovirotherapy of malignant melanoma with a targeted and armed oncolytic measles virus.
Kaufmann JK; Bossow S; Grossardt C; Sawall S; Kupsch J; Erbs P; Hassel JC; von Kalle C; Enk AH; Nettelbeck DM; Ungerechts G
J Invest Dermatol; 2013 Apr; 133(4):1034-42. PubMed ID: 23223133
[TBL] [Abstract][Full Text] [Related]
25. Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway.
Li H; Soria C; Griscelli F; Opolon P; Soria J; Yeh P; Legrand C; Vannier JP; Belin D; Perricaudet M; Lu H
Hum Gene Ther; 2005 Oct; 16(10):1157-67. PubMed ID: 16218777
[TBL] [Abstract][Full Text] [Related]
26. BioKnife, a uPA activity-dependent oncolytic Sendai virus, eliminates pleural spread of malignant mesothelioma via simultaneous stimulation of uPA expression.
Morodomi Y; Yano T; Kinoh H; Harada Y; Saito S; Kyuragi R; Yoshida K; Onimaru M; Shoji F; Yoshida T; Ito K; Shikada Y; Maruyama R; Hasegawa M; Maehara Y; Yonemitsu Y
Mol Ther; 2012 Apr; 20(4):769-77. PubMed ID: 22314292
[TBL] [Abstract][Full Text] [Related]
27. MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism.
Leber MF; Bossow S; Leonard VH; Zaoui K; Grossardt C; Frenzke M; Miest T; Sawall S; Cattaneo R; von Kalle C; Ungerechts G
Mol Ther; 2011 Jun; 19(6):1097-106. PubMed ID: 21468006
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic potential of oncolytic measles virus: promises and challenges.
Galanis E
Clin Pharmacol Ther; 2010 Nov; 88(5):620-5. PubMed ID: 20881957
[TBL] [Abstract][Full Text] [Related]
29. The Role of Neutrophils in Measles Virus-mediated Oncolysis Differs Between B-cell Malignancies and Is Not Always Enhanced by GCSF.
Dey A; Zhang Y; Castleton AZ; Bailey K; Beaton B; Patel B; Fielding AK
Mol Ther; 2016 Feb; 24(1):184-92. PubMed ID: 26278331
[TBL] [Abstract][Full Text] [Related]
30. Measles virus entry through the signaling lymphocyte activation molecule governs efficacy of mantle cell lymphoma radiovirotherapy.
Miest TS; Frenzke M; Cattaneo R
Mol Ther; 2013 Nov; 21(11):2019-31. PubMed ID: 23913184
[TBL] [Abstract][Full Text] [Related]
31. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.
Galanis E; Hartmann LC; Cliby WA; Long HJ; Peethambaram PP; Barrette BA; Kaur JS; Haluska PJ; Aderca I; Zollman PJ; Sloan JA; Keeney G; Atherton PJ; Podratz KC; Dowdy SC; Stanhope CR; Wilson TO; Federspiel MJ; Peng KW; Russell SJ
Cancer Res; 2010 Feb; 70(3):875-82. PubMed ID: 20103634
[TBL] [Abstract][Full Text] [Related]
32. Oncolytic measles virus efficacy in murine xenograft models of atypical teratoid rhabdoid tumors.
Studebaker AW; Hutzen B; Pierson CR; Shaffer TA; Raffel C; Jackson EM
Neuro Oncol; 2015 Dec; 17(12):1568-77. PubMed ID: 25838138
[TBL] [Abstract][Full Text] [Related]
33. Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter.
Msaouel P; Iankov ID; Allen C; Aderca I; Federspiel MJ; Tindall DJ; Morris JC; Koutsilieris M; Russell SJ; Galanis E
Mol Ther; 2009 Dec; 17(12):2041-8. PubMed ID: 19773744
[TBL] [Abstract][Full Text] [Related]
34. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy.
Reddi HV; Madde P; McDonough SJ; Trujillo MA; Morris JC; Myers RM; Peng KW; Russell SJ; McIver B; Eberhardt NL
Cancer Gene Ther; 2012 Sep; 19(9):659-65. PubMed ID: 22790962
[TBL] [Abstract][Full Text] [Related]
35. Polyinosinic acid decreases sequestration and improves systemic therapy of measles virus.
Liu YP; Tong C; Dispenzieri A; Federspiel MJ; Russell SJ; Peng KW
Cancer Gene Ther; 2012 Mar; 19(3):202-11. PubMed ID: 22116376
[TBL] [Abstract][Full Text] [Related]
36. Urokinase-type plasminogen activator receptor transcriptionally controlled adenoviruses eradicate pancreatic tumors and liver metastasis in mouse models.
Huch M; Gros A; José A; González JR; Alemany R; Fillat C
Neoplasia; 2009 Jun; 11(6):518-28, 4 p following 528. PubMed ID: 19484141
[TBL] [Abstract][Full Text] [Related]
37. Recombinant measles virus induces cytolysis of cutaneous T-cell lymphoma in vitro and in vivo.
Künzi V; Oberholzer PA; Heinzerling L; Dummer R; Naim HY
J Invest Dermatol; 2006 Nov; 126(11):2525-32. PubMed ID: 16960554
[TBL] [Abstract][Full Text] [Related]
38. Specific elimination of CD133+ tumor cells with targeted oncolytic measles virus.
Bach P; Abel T; Hoffmann C; Gal Z; Braun G; Voelker I; Ball CR; Johnston IC; Lauer UM; Herold-Mende C; Mühlebach MD; Glimm H; Buchholz CJ
Cancer Res; 2013 Jan; 73(2):865-74. PubMed ID: 23293278
[TBL] [Abstract][Full Text] [Related]
39. A recombinant measles virus vaccine strain rMV-Hu191 has oncolytic effect against human gastric cancer by inducing apoptotic cell death requiring integrity of lipid raft microdomains.
Lv Y; Zhou D; Hao XQ; Zhu MY; Zhang CD; Zhou DM; Wang JH; Liu RX; Wang YL; Gu WZ; Shen HQ; Chen X; Zhao ZY
Cancer Lett; 2019 Sep; 460():108-118. PubMed ID: 31226409
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-mediated multi-tissue detargeting of oncolytic measles virus.
Baertsch MA; Leber MF; Bossow S; Singh M; Engeland CE; Albert J; Grossardt C; Jäger D; von Kalle C; Ungerechts G
Cancer Gene Ther; 2014 Sep; 21(9):373-80. PubMed ID: 25145311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
